Related Experiment Video

Updated: Jun 22, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

M Monami1, I Iacomelli, N Marchionni

  • 1Department of Critical Care Medicine, University of Florence and Azienda Ospedaliera Careggi, Florence, Italy. mmonami@libero.it

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|June 12, 2009
PubMed
Abstract

Insights

Dipeptidyl Peptidase-4 (DPP-4) inhibitors significantly lower HbA1c in type 2 diabetes patients with minimal hypoglycemia risk. Further research is needed to confirm long-term safety.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • The efficacy and safety of Dipeptidyl Peptidase-4 (DPP-4) inhibitors for type 2 diabetes management remain subjects of ongoing discussion.
  • Previous meta-analyses may not have incorporated recent clinical trial data, necessitating an updated comprehensive review.

Purpose of the Study:

  • To conduct a meta-analysis of all available randomized controlled trials (RCTs) evaluating DPP-4 inhibitors in type 2 diabetes.
  • To assess the impact of DPP-4 inhibitors on HbA1c, BMI, hypoglycemia, and adverse events, including cardiovascular outcomes and all-cause mortality.

Main Methods:

  • A systematic meta-analysis was performed on 41 RCTs (including 9 unpublished studies) of type 2 diabetic patients treated with DPP-4 inhibitors for over 12 weeks.
  • Data on HbA1c, BMI, hypoglycemia, and other adverse events were extracted and analyzed.

Main Results:

  • DPP-4 inhibitors demonstrated a significant reduction in HbA1c compared to placebo (-0.7% [-0.8:-0.6]) with a low incidence of hypoglycemia.
  • Efficacy was consistent whether DPP-4 inhibitors were used as monotherapy or in combination with other antidiabetic agents.
  • The analysis indicated a non-significant trend towards reduced risk for cardiovascular events (0.76 [0.46-1.28]) and all-cause death (0.78 [0.40-1.51]).

Conclusions:

  • DPP-4 inhibitors effectively lower HbA1c levels in type 2 diabetes patients, offering an advantage of no weight gain and a low risk of hypoglycemia.
  • While effective, their HbA1c-lowering capacity is less pronounced than that of sulfonylureas.
  • Long-term safety data, particularly regarding cardiovascular outcomes, require further investigation to fully elucidate the risk-benefit profile.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...